Pharmaceutical business
- * While on May 7th, 2025, the Company announced entering into an agreement with Shionogi & Co., Ltd to transfer the pharmaceutical business and our stake in TORII PHARMACEUTICAL CO., LTD. ("Torii"), a consolidated subsidiary of JT, the JT Group's performance and initiatives described on this page include those associated with the pharmaceutical business and Torii. Please see the press releases on our website for the details
Overview
JT is committed to the research and development of world-class, innovative drugs.
As this business has a direct impact on human health and life, we not only strictly comply with all laws, regulations, and industry standards, but are also guided by a strong sense of ethics and responsibility. This is particularly the case in areas such as clinical trials and promoting drugs, as well as animal experiments and managing chemical substances.
We operate our pharmaceutical business based on our business Purpose , “Respecting science, technology and people, we will contribute to patients’ lives.”
JT concentrates on R&D, while Torii Pharmaceutical Co., Ltd. is in charge of sales and promotion in the Japanese domestic market.
- Note: Regarding manufacturing, we outsource the entire process of manufacturing operations to contracted factories. Outside of Japan, we do not have a sales function, but we do license drugs to other pharmaceutical manufacturers.
Our pharmaceutical business value chain*
- * This diagram represents the value chain of products developed by JT, and sold and promoted by Torii Pharmaceutical (As of FY24).
Pharmaceutical Business Sustainability
The JT Group Materiality sets out five priority material issues. Based on the JT Group Materiality, we have set the JT Group Sustainability Targets with specific goals and initiatives. The following are our primary initiatives in the pharmaceutical business.
Progress of Sustainability Initiatives in the Pharmaceutical Business to 2024
